Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Basel University Hospital
Immunotherapy with NK cells may mitigate GVHD during HSCT
October 26th, 2005
Immunotherapy with natural killer cells may mitigate graft-versus-host disease during hematopoietic stem cell transplantation. "Adoptive immunotherapy using natural killer (NK) cells may prove useful, especially in situations where infusion of T cells is impractical such as in recipients of haploidentical stem cell transplantation (HSCT) from haploidentical donors. "NK cells may induce potent antileukemic and possibly antirejection activity and may even mitigate graft versus host disease (GvHD)," scientists writing in the journal Bone Marrow Transplantation report. "Whether such effects are clinically important and whether...
Source: Elder Law Weekly (2005-10-26)
|
